Staff Reports
Megyn Kelly’s recent chat with Dr. Sean O’Mara turned a medical niche into a headline: not all fat is created equal. The pair focused on visceral fat — the sneaky stuff wrapped around your organs — and why it deserves more worry than the fat you can pinch. If you still think a flat stomach or a six‑pack is a clean bill of health, this segment is a wake‑up call.
What visceral fat actually is
Visceral fat — aka visceral adipose tissue (VAT) — sits deep inside your belly. It hugs your liver, pancreas and intestines. Unlike the squishy fat under your skin (subcutaneous fat), VAT acts like an unwanted little factory. It pumps out free fatty acids and inflammatory signals such as IL‑6 and TNF‑α. Those chemicals can make your liver grumpy, wreck insulin action, and stir up blood vessel inflammation. In plain English: visceral fat messes with your body’s normal controls and raises your cardiometabolic risk.
The hard evidence: worse outcomes, not just aesthetics
This isn’t just talk radio alarmism. Big reviews and meta‑analyses show that measures of central fatness — waist circumference, waist‑to‑hip ratio, and imaging of visceral fat — predict higher rates of type 2 diabetes, heart disease, and even death, independent of BMI. The BMJ and other journals make a clear point: central adiposity is a real risk marker. So no, your mirror might not be telling the whole truth about your health.
How doctors measure it — and what actually cuts it down
Practical screening vs. gold‑standard tests
In the real world, clinicians use a tape measure. A waist around 40 inches for men or 35 inches for women is commonly used to flag higher risk, though doctors adjust for ethnicity. The true gold standards are CT, MRI or DEXA scans — but those are costly and used mainly in research. So the tape will do, if you use it honestly.
What reduces visceral fat? The short list is familiar: sustained weight loss, aerobic and combined exercise, and better diets. Randomized trials show regular aerobic training drops VAT even beyond simple weight change. Lately, the new weight‑loss drugs — GLP‑1 receptor agonists like semaglutide and the twin‑agonist tirzepatide — have shown measurable cuts in visceral fat on DEXA/MRI substudies. Yes, the drugs change body composition, not just the number on the scale. But don’t confuse a promising pill ad with a medical plan — these medicines matter, but they’re part of a toolbox, not a miracle.
Don’t be fooled, and don’t panic
There are two useful takeaways: first, visceral fat is biologically different and dangerous enough to deserve attention. Second, appearance can lie — “thin outside, fat inside” is a real pattern. That said, the science still debates cause vs. consequence in places; visceral fat is a key marker, but metabolism is complicated. My conservative advice? Skip the fear porn and take responsibility. Measure your waist, move more, eat less processed sugar, talk to your doctor about realistic steps — and if a medication is right for you, use it under medical supervision. The chest‑thumping of quick fixes won’t save you, but sensible action will.
